Modeling follicular thyroid cancer for future therapies.

Area of Science:

• Oncology
• Translational Research
• Molecular Biology

Background:

• Therapeutic options for undifferentiated metastatic thyroid carcinomas are limited.
• Subcutaneous xenograft models are standard but often fail to predict clinical trial outcomes.
• There is a need for more predictive preclinical models of metastatic thyroid cancer.

Purpose of the Study:

• To review advances in modeling follicular thyroid carcinoma with distant metastasis.
• To highlight the utility of genetically engineered mouse models (GEMMs) in preclinical studies.
• To emphasize the significance of GEMMs for clinical applications in thyroid cancer.

Main Methods:

• Review of recent literature on GEMMs for metastatic thyroid carcinoma.
• Analysis of pathological progression and immunocompetent environments in GEMMs.
• Comparison of GEMMs with traditional xenograft models.

Main Results:

• GEMMs exhibit pathological and progression similarities to human thyroid cancers.
• GEMMs offer an immunocompetent environment for evaluating molecular targets.
• GEMMs demonstrate improved predictive value for clinical trial outcomes compared to xenografts.

Conclusions:

• Genetically engineered mouse models represent a significant advancement for preclinical evaluation of metastatic thyroid cancer.
• GEMMs are crucial for identifying and validating novel therapeutic targets.
• The use of GEMMs is essential for improving the translation of preclinical findings to clinical applications in thyroid cancer treatment.